About BioTrack Capital
BioTrack Capital is a venture capital firm founded in 2017. It is primarily based out of Shanghai, China. As of Aug 2026, BioTrack Capital is an active investor, having invested in 63 companies, with 4 new investments in the last 12 months. It primarily invests in Series A round in China based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Seed round of Convergen Pharmaceuticals Overall, BioTrack Capital portfolio has seen 1 unicorn and 8 IPOs including key companies like BlossomHill Therapeutics, CF PharmTech and Shenzhen Jingfeng Medical Technology. A lot of funds co-invest with BioTrack Capital, with names like Qiming Venture Partners sharing a substantial percentage of its portfolio. BioTrack Capital has team of 7 people including 3 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 5 more
Portfolio IPOs
Portfolio Unicorns
Deals in last 12 months
BioTrack Capital's List of Top Investments
BioTrack Capital has a portfolio of 63 companies, one of which is a Unicorn. Their most notable investments are in SMT Group and Jiangsu Huili Biotechnology.Their portfolio spans across China, United States, Cayman Islands and 1 more locations. They have invested in Life Sciences, High Tech, HealthTech and 14 other sectors, across stages such as Series A, Series B and 5 more. Here is the list of top investments by BioTrack Capital:Developer of small molecule oncology therapeutics for treating cancer patients. Research focuses on designing chemical compounds that target specific biological drivers of disease. These therapeutic candidates aim to address resistance mechanisms in various forms of malignancy. The development process involves clinical evaluation of drug candidates to assess safety and efficacy in human subjects.
Key facts about BlossomHill Therapeutics
- Founded Year: 2020
- Location: San Diego (United States)
- Stage: Public
- Total Funding till date: $257M
- Employee Count: 69 as on Sep 30, 2026
- Investors: Colt Ventures, Janus Henderson Investors and 8 Others
- Latest Funding Round: Series B, Nov 25, 2025, $*****
- Highlight: Public
2. PAQ
Developer of small molecule therapeutics for neurodegenerative disease. The company offers autophagosome-tethering compounds that enhances the degradation of disease-causing protein and non-protein targets.
Key facts about PAQ
- Founded Year: 2020
- Location: Cambridge (United States)
- Stage: Series B
- Total Funding till date: $111M
- Investors: MSA Capital, Sherpa Healthcare Partners and 8 Others
- Latest Funding Round: Series B, Jan 26, 2026, $*****
- Highlight: Editors' Pick
3. CF PharmTech
CF PharmTech is a Chinese, commercial-stage, specialty Respiratory-focused drug-delivery development company, and CDMO. The company develops formulations and devices required for the metered-dose inhaler, inhalation powder, nasal spray, and blow-fill-seal products. The disease areas focused on are Rhinitis, Asthma, and COPD, and also other respiratory diseases. The company develops new formulations for existing and new substances, new delivery systems for existing and new APIs, and working with independent research teams to develop new products.
Key facts about CF PharmTech
- Founded Year: 2007
- Location: Suzhou (China)
- Stage: Public
- Total Funding till date: $206M
- Employee Count: 69 as on Sep 30, 2026
- Investors: CCB International, SDIC Innovation and 21 Others
- Latest Funding Round: Series F, Jul 02, 2020, $*****
- Highlight: Public
Developer of surgical robot instruments. It manufactures surgical robots, devices and instruments for the healthcare sector. The companys products include robotic surgical systems for laparoscopic surgery, natural orifice surgery, and traditional invasive surgery.
Key facts about Shenzhen Jingfeng Medical Technology
- Founded Year: 2017
- Location: Shenzhen (China)
- Stage: Public
- Total Funding till date: $307M
- Investors: Temasek, Greater Bay Area Homeland Investments and 17 Others
- Latest Funding Round: Series C, Nov 08, 2021, $*****
- Highlight: Public
5. EdiGene
Developer of genome editing technology for the treatment of cancer and genetic disease. The company has developed LEAPER technology, which is an in vivo oligonucleotide-based RNA single-base editing technology used for the treatment of Hurler syndrome. The company's in vitro therapy includes ET-01 for β-thalassemia major and the allogeneic CAR-T ET-02 for cancer.
Key facts about EdiGene
- Founded Year: 2015
- Location: Changping District (China)
- Stage: Series B
- Total Funding till date: $165M
- Employee Count: 46 as on Sep 30, 2026
- Investors: Loayal Valley Capital, 3H Health Investment and 16 Others
- Latest Funding Round: Series B, Apr 21, 2021, $*****
- Highlight: Editors' Pick
BioTrack Capital's Year-on-Year Investment Trends
BioTrack Capital has invested in 63 companies over the last 8 years, with an average of 5 new investments annually in the last 5 years. In 2025, it made 5 investments, while as of Aug 2026, it has made 2 investments in this year. Its most recent first time investment was in Convergen Pharmaceuticals and most recent follow-on round was in Acchrom-Tech.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 2 | 0 | 2 |
2025 | 5 | 0 | 5 |
2024 | 3 | 0 | 3 |
2023 | 0 | 2 | 2 |
2022 | 12 | 1 | 13 |
2021 | 14 | 2 | 16 |
2020 | 9 | 1 | 10 |
2019 | 4 | 1 | 5 |
2018 | 1 | 0 | 1 |
BioTrack Capital's Investments by Stage
BioTrack Capital has made 18 investments in Series A stage with an average round size of $32.6M, 14 investments in Series B stage with an average round size of $65.6M and 7 investments in Series C stage with an average round size of $197M.Stage of entry | No. of Investments |
|---|---|
Series A | 18 |
Series B | 14 |
Series C | 7 |
Seed | 5 |
Angel | 4 |
Others | 2 |
Note: We have considered here, only first round of investments
BioTrack Capital's Investments by Sector
BioTrack Capital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Healthcare, Enterprise Applications and HealthTech. Notably, it has invested in 43 Enterprise (B2B) companies, 42 Tech companies, 8 Tech hardware companies and at least 6 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 29 |
High Tech | 12 |
Healthcare | 11 |
Enterprise Applications | 6 |
HealthTech | 5 |
Others | 18 |
Note: We have considered here, only first round of investments
BioTrack Capital's Investments by Geography
BioTrack Capital has made most investments in China (40), followed by United States where it has made 7 investments.Country | No. of Investments |
|---|---|
China | 40 |
United States | 7 |
Cayman Islands | 1 |
Singapore | 1 |
Note: We have considered here, only first round of investments
BioTrack Capital's recent investments
BioTrack Capital has made 2 investments in 2026 so far - Convergen Pharmaceuticals and Syneron Bio.Here are the most recent investments by BioTrack Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Aug 31, 2026 | China | Seed | 8161 | ||
Mar 31, 2026 | China | Series B | 8200 | [+11] | |
Dec 15, 2025 | China | Series B | 1284 | ||
Nov 25, 2025 | United States | Series B | 7398 | ||
Sep 05, 2025 | United States | Series A | 3106 | [+3] |
Unicorns in BioTrack Capital's Portfolio
BioTrack Capital has 1 unicorn in its portfolio - Abogen Biosciences. The most recent unicorn in their portfolio is Abogen Biosciences which became a unicorn in 2021.Here is a list of unicorns in BioTrack Capital's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
56 | Developer of mRNA-based therapeutics for cancer and infectious diseases | 2019 | Suzhou | Series C | ptunkci |
IPOs and Publicly Listed companies in BioTrack Capital's Portfolio
8 of BioTrack Capital's portfolio companies have become public. BlossomHill Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Aug 2026 at marketcap of $490M and Shenzhen Jingfeng Medical Technology got listed on the Hong Kong Exchanges (HKG) at marketcap of $2.15B.Here are BioTrack Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 07, 2026 | Nov 25, 2025 | Series B | 7837 | |
Jan 08, 2026 | Jan 22, 2021 | Series B | 5322 | |
Oct 08, 2025 | Jul 02, 2020 | Series F | 9408 | |
Apr 15, 2022 | - | - | 3229 | |
Mar 22, 2022 | Sep 23, 2020 | Series C | 3675 |
Team profile of BioTrack Capital
BioTrack Capital has a team of 7 members including 3 Partners and 2 Principals located in China. BioTrack Capital's team does not sit on the board of any company as of now.Here is a list of all team members in BioTrack Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Shanghai | - | ||
Partner | Shanghai | - | - | |
Partner | - | - | ||
Principal | Shanghai | - | ||
Principal | Shanghai | - | - |
Co-investors of BioTrack Capital
Over the past 8 years, 311 investors have co-invested in BioTrack Capital's portfolio companies. This includes funds and angels.
- Invested before BioTrack Capital: Huagai Capital, Alwin Capital and 105 others have invested in rounds before BioTrack Capital. There are 3 companies where Huagai Capital has invested before BioTrack Capital and 3 companies where Alwin Capital has invested before BioTrack Capital.
- Top Co-investors of BioTrack Capital: 143 investors entered a company along with BioTrack Capital. These include investors like Qiming Venture Partners (5 companies).
- Invested after BioTrack Capital: A total of 61 investors have invested in BioTrack Capital's portfolio after their investments. Top Investors include Sequoia Capital (2 companies), Temasek (2 companies) and Mirae Asset (2 companies).
Recent News related to BioTrack Capital
•
Convergen Secures $15 Million Seed+ Financing to Advance Therapeutics for Protein Aggregation DiseasesPR Newswire•Aug 31, 2026•BioTrack Capital, Convergen Pharmaceuticals
•
Aureka Biotechnologies Raises US$100 Million Series B to Build a Biological World Model for Drug DiscoveryPR Newswire•Aug 11, 2026•Aureka Biotechnologies, Granite Asia, NRL Capital, Matrix Partners China and 3 others
•
Syneron Bio Closes $150M Series B FinancingFinSMEs•Apr 03, 2026•LAV, Global League, True Light Capital, 5Y Capital and 10 others
•
BlossomHill Therapeutics Secures $84M for Macrocyclic EGFR ApproachEndpoints•Dec 10, 2025•BlossomHill Therapeutics, BioTrack Capital, Cormorant Asset Management, Vivo Capital and 4 others
•
Rapafusyn Pharmaceuticals Closes $44 Million Series A Financing for Molecular Glue Drug Discovery PlatformAgencia EFE•Sep 04, 2025•Rapafusyn, Yonjin Capital, BioTrack Capital, 3E Bioventures Capital and 5 others
•
Chinese biotech Minghui raises $131M to advance its PD-1xVEGF bispecificEndpoints•Aug 07, 2025•Minghui Pharmaceutical, BioTrack Capital, Orbimed, Qiming Venture Partners and 1 other
•
Sirius Therapeutics Secures Nearly $50 Million in Series B2 Fundingintelligence360•May 22, 2025•Sirius Therapeutics, Creacion Ventures, Orbimed, BioTrack Capital
•
Sirius Therapeutics Secures Nearly $50M in Series B2 FundingFinSMEs•May 10, 2025•Sirius Therapeutics, BioTrack Capital, Orbimed, Creacion Ventures
•
Sirius Therapeutics Announces Nearly $50 Million FinancingBusiness Wire•May 09, 2025•Sirius Therapeutics, BioTrack Capital, Orbimed, Creacion Ventures
•
